ANTHERA PHARMACEUTICALS INC
ANTH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ANTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2018.
Tracking 2 pipeline candidates for ANTHERA PHARMACEUTICALS INC.
Run ANTHERA PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ANTHERA PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
2.6 months
D/E 0.61
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 8.4%
- Days to cover
- 2.1
- Shares short
- 2,015,026
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANTH short interestFrequently asked questions
What is ANTHERA PHARMACEUTICALS INC's lead drug candidate?
ANTHERA PHARMACEUTICALS INC's most advanced tracked candidate is blisibimod (Phase 2) for Immunoglobulin A nephropathy (IgA nephropathy).
Who is the CEO of ANTHERA PHARMACEUTICALS INC?
Craig Thompson is the chief executive officer of ANTHERA PHARMACEUTICALS INC (ANTH).
Where is ANTHERA PHARMACEUTICALS INC headquartered?
ANTHERA PHARMACEUTICALS INC (ANTH) is headquartered in Houston, TX, United States.
What therapeutic areas does ANTHERA PHARMACEUTICALS INC focus on?
ANTHERA PHARMACEUTICALS INC develops therapies across Oncology, Immunology, Pain, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.